Immunology of Infectious Disease News Volume 8.46 | Dec 9 2020

May 12, 2022

IIDN 8.46 | Dec 9 2020

Immunology of Infectious Disease News by STEMCELL Technologies

Vol. 8.46 – 9 December, 2020

TOP STORY

Genetic
Screens Identify Host Factors for SARS-CoV-2 and Common Cold Coronaviruses

Scientists conducted genome-wide CRISPR screens in cells infected by SARS-CoV-2 as well as two seasonally circulating common cold coronaviruses, OC43 and 229E.
[Cell]

Abstract Full Article
Press Release

Start Fast. Finish Faster. Streamline your assays with purified human primary cells from STEMCELL Technologies. View products now.

PUBLICATIONSRanked by the impact factor of the journal

SARS-CoV-2

Opposing Activities of IFITM Proteins in SARS-CoV-2 Infection

Researchers showed that SARS‐CoV‐2 Spike‐pseudotyped virus and genuine SARS‐CoV‐2 infections were generally restricted by human and mouse IFITM1, IFITM2, and IFITM3, using gain‐ and loss‐of‐function approaches.
[EMBO Journal]

Abstract
Press Release

Defining
the Features and Duration of Antibody Responses to SARS-CoV-2 Infection Associated with Disease Severity and Outcome

Investigators analyzed 983 longitudinal plasma samples from 79 hospitalized COVID-19 patients and 175 SARS-CoV-2-infected outpatients and asymptomatic individuals.
[Science Immunology]

Full Article

A
Highly Immunogenic and Effective Measles Virus-Based Th1-Biased COVID-19 Vaccine

Scientists generated measles virus-based vaccine candidates expressing the SARS-CoV-2 spike glycoprotein.
[Proceedings of the National Academy of Sciences of the United States of America]

Full Article
Press Release

The
Roborovski Dwarf Hamster Is a Highly Susceptible Model for a Rapid and Fatal Course of SARS-CoV-2 Infection

Researchers compared the susceptibilities of three dwarf hamster species to SARS-CoV-2 and introduce the Roborovski dwarf hamster as a highly susceptible COVID-19 model with consistent and fulminant clinical signs.
[Cell Reports]

Full Article Graphical Abstract

Investigation
of COVID-19 Comorbidities Reveals Genes and Pathways Coincident with the SARS-CoV-2 Viral Disease

Investigators conducted a bioinformatics analysis of COVID-19 comorbidity-associated gene sets, identifying genes and pathways shared among the comorbidities, and evaluated current knowledge about these genes and pathways as related to current information about SARS-CoV-2 infection.
[Scientific Reports]

Full Article

HMGB1 as a Potential Biomarker and Therapeutic Target for Severe COVID-19

The authors report that high mobility group box 1 (HMGB1), a prototypical damage-associated molecular pattern and a central mediator of lethal inflammation, could be a potential target for innovative therapeutic strategies for COVID-19.
[Heliyon]

Full Article

Enhancement
of the IFN-β-Induced Host Signature Informs Repurposed Drugs for COVID-19

Researchers used a host-directed approach, which focused on cellular responses to diverse small-molecule treatments, to identify potentially effective drugs for COVID-19.
[Heliyon]

Full Article

MORE IMMUNOLOGY OF INFECTIOUS DISEASE

Human
T-Bet Governs Innate and Innate-Like Adaptive IFN-γ Immunity against Mycobacteria

Investigators report a patient with mycobacterial disease due to inherited deficiency of the transcription factor T-bet. Human T-bet deficiency underlaid mycobacterial disease by preventing the development of innate and innate-like adaptive lymphocytes.
[Cell]

Abstract Graphical Abstract

TMEM41B Is a Pan-Flavivirus Host Factor

To identify host factors required for flavivirus infection, researchers performed full-genome loss of function CRISPR-Cas9 screens. Based on these results they focused their efforts on characterizing the roles that TMEM41B and VMP1 play in the virus replication cycle.
[Cell]

Abstract

SHP-1
Regulates Antigen Cross-Presentation and Is Exploited by Leishmania to Evade Immunity

Scientists demonstrated that SHP-1 inhibition improved CD11c⁺ cell-based vaccination against the parasite. They found increased cross-priming of CD8⁺ T lymphocytes in Leishmania-infected mice deficient for Mincle or with a selective loss of SHP-1 in CD11c⁺ cells.
[Cell Reports]

Full Article Graphical Abstract

Virtual Conference Exhibition: Immunology

REVIEWS

COVID-19: Neonatal–Perinatal Perspectives

The authors provide a comprehensive overview of neonatal–perinatal perspectives of COVID-19, ranging from the basic science of infection and recommendations for care of pregnant women and neonates to important psychosocial, ethical, and racial/ethnic topics emerging as a result of both the pandemic and the response of the healthcare community to the care of infected individuals.
[Journal of Perinatology]

Full Article

INDUSTRY AND POLICY NEWS

US FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age and Older

Pfizer, Inc. announced that the FDA accepted for priority review a Biologics License Application for its 20-valent pneumococcal conjugate vaccine candidate, as submitted for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults ages 18 years and older.
[Pfizer, Inc. (BusinessWire, Inc)]

Press Release

Rheonix COVID-19^™ MDx Assay Receives Expanded FDA Emergency Use Authorization to Include Saliva as a Sample Type

Rheonix, Inc. announced that the FDA has issued an expanded Emergency Use Authorization for the Rheonix COVID-19^™ MDx Assay and now allows the use of saliva as an approved sample type.
[Rheonix, Inc. (BusinessWire, Inc)]

Press Release

Xlear Submits COVID-19 Pre-Emergency Use Authorization Request with FDA Regarding Use of Xlear Nasal Spray to Help in Combating SARS-CoV-2

Xlear filed a Pre-Emergency Use Authorization (Pre-EUA) request with the FDA. The Pre-EUA is a first step in seeking authorization of Xlear Nasal Spray as a new hygiene tool to help in combat the SARS-CoV-2 virus, the virus that causes COVID-19.
[Xlear (BusinessWire, Inc)]

Press Release

FEATURED EVENT

Genetic
Screens Identify Host Factors for SARS-CoV-2 and Common Cold Coronaviruses

Opposing Activities of IFITM Proteins in SARS-CoV-2 Infection

Defining
the Features and Duration of Antibody Responses to SARS-CoV-2 Infection Associated with Disease Severity and Outcome

A
Highly Immunogenic and Effective Measles Virus-Based Th1-Biased COVID-19 Vaccine

The
Roborovski Dwarf Hamster Is a Highly Susceptible Model for a Rapid and Fatal Course of SARS-CoV-2 Infection

Investigation
of COVID-19 Comorbidities Reveals Genes and Pathways Coincident with the SARS-CoV-2 Viral Disease

HMGB1 as a Potential Biomarker and Therapeutic Target for Severe COVID-19

Enhancement
of the IFN-β-Induced Host Signature Informs Repurposed Drugs for COVID-19

Human
T-Bet Governs Innate and Innate-Like Adaptive IFN-γ Immunity against Mycobacteria

TMEM41B Is a Pan-Flavivirus Host Factor

SHP-1
Regulates Antigen Cross-Presentation and Is Exploited by Leishmania to Evade Immunity

COVID-19: Neonatal–Perinatal Perspectives

US FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age and Older

Rheonix COVID-19^™ MDx Assay Receives Expanded FDA Emergency Use Authorization to Include Saliva as a Sample Type

Xlear Submits COVID-19 Pre-Emergency Use Authorization Request with FDA Regarding Use of Xlear Nasal Spray to Help in Combating SARS-CoV-2

Peptalk

> See All Events

Postdoctoral Positions – Virology

PhD
Student – RNA Immunoengineering Lab

Postdoctoral Position – Immunology

Tier 2 Canada Research Chair – Immunology and Inflammation

Senior
Research Technologist – Inflammation and Immunity

> See All Jobs